A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia

Archives of Pharmacal Research

Volumn 33, Issue 11, 2010, Pages 1761-1769

  Feng, Juan ^a   Li, Xiang ^a   Yang, Xiaolan ^a   Zhang, Chun ^a   Yuan, Yonghua ^a   Pu, Jun ^a   Zhao, Yunsheng ^a   Xie, Yanling ^a   Yuan, Huidong ^a   Bu, Youquan ^a   Liao, Fei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Half life time; Hyperuricemia; Mathematic modeling; Pharmacodynamics; Pharmacokinetics; Uricase

Indexed keywords

MACROGOL; MACROGOL 5000; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; ENZYME ACTIVITY; HYPERURICEMIA; MALE; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; RABBIT; RAT; URIC ACID BLOOD LEVEL;

ANIMALS; BACILLUS; GOUT; HALF-LIFE; HYPERURICEMIA; MALE; POLYETHYLENE GLYCOLS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; URATE OXIDASE; URIC ACID; XANTHINE;

EID: 78751476321     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-1108-2     Document Type: Article

References (47)

1. Bandukwala, F., Huang, M., Zaltzman, J. S., Nash, M. M., and Prasad, G. V., Association of uric acid with inflamma-tion, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am. J. Cardiol., 103, 867-871 (2009).
2. Baum, H., Hubsche, G., and Mahler, H. R., Studies on uri-case. II. The enzyme-substrate complex. Biochim. Biophys. Acta, 22, 514-527 (1956).
3. Bertrand, Y., Mechinaud, F., Brethon, B., Mialou, V., Auvrignon, A., Nelken, B., Notz-Carrere, A., Plantaz, D., Patte, C, Urbieta, M., Baruchel, A., and Leverger, G., SFCE recom-mendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. J. Pediatr. Hematol. Oncol., 30, 267-271 (2008).
4. Biggers, K. and Scheinfeld, N., Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. Curr. Opin. Investig. Drugs, 9, 422-429 (2008).
5. Bomalaski, J. S., Holtsberg, F. W., Ensor, C. M., and Clark, M. A., Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J. Rheumatol., 29, 1942-1949 (2002).
6. Bomalaski, J. S. and Clark, M. A., Serum uric acid-lowering therapies: where are we heading in management of hyper-uricemia and the potential role of uricase. Curr. Rheu-matol. Rep., 6, 240-247 (2004).
7. Bongaerts, G. P. A., Uitzetter, J., Brouns, R., and Vogels, G. D., Uricase of Bacillus fastidiosus: properties and regulation of synthesis. Biochem. Biophys. Acta, 527, 348-358 (1978).
8. Borinstein, S. C., Xu, M., and Hawkins, D. S., Methemoglo-binemia and hemolytic anemia caused by rasburicase ad-ministration in a newly diagnosed child with Burkitt lym-phoma/leukemia. Pediatr. Blood Cancer, 50, 189 (2008).
9. Bradford, M. M., A rapid and sensitive method for the qu-antitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
10. Browning, L. A. and Kruse, J. A., Hemolysis and methemo-globinemia secondary to rasburicase administration. Ann. Pharmacother., 39, 1932-1935 (2005).
11. Chohan, S. and Becker, M. A., Update on emerging urate-lowering therapies. Curr. Opin. Rheumatol., 21, 143-149 (2009).
12. Conley, T. G. and Priest, D. G., Thermodynamics and stoichio-metry of the binding of substrate analogues to uricase. Biochem. J., 187, 727-732 (1980).
13. Danhof, M., de Jongh, J., De Lange, E. C., Della Pasqua, O. E., Ploeger, B. A., and Voskuyl, R. A., Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems an-alysis. Annu. Rev. Pharmacol. Toxicol., 47, 357-400 (2007).
14. Danhof, M., de Lange, E. C, Della Pasqua, O. E., Ploeger, B. A., and Voskuyl, R. A., Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci., 29, 186-191 (2008).
15. Davidson, M. B., Thakkar, S., Hix, J. K., Bhandarkar, N. D., Wong, A., and Schreiber, M. J., Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am. J. Med., 116, 546-554 (2004).
16. Ducros, J., Saingra, S., Rampal, M., Coulange, C., Barbe, M. C., and Verzetti, G., Hemolytic anemia due to G6PD defi-ciency and urate oxidase in a kidney-transplant patient. Clin. Nephrol., 35, 89-90 (1991).
17. Feig, D. I., Kang, D. H., and Johnson, R. J., Uric acid and car-diovascular risk. N. Engl. J. Med., 359, 1811-1821 (2008).
18. Fridovich, I., The competitive inhibition of uricase by oxon-ate and by related derivatives of s-triazines. J. Biol. Chem., 240, 2491-2494 (1965).
19. Guo, R, Li, S. B., Zhao, L. N, Zhao, Y. S, Lu, W, Yuan, P., Deng, P., and Liao F., A new linearly-combined bi-expo-nential model for kinetic analysis of the isometric relaxa-tion process of Bufo gastrocnemius under electric stimula-tion in vitro. J. Zhejiang Univ. Sci. B, 8, 867-874 (2007).
20. Hande, K. R., Perini, F., Putterman, G. J., and Elm, R., Hy-perxanthinemia interferes with serum uric acid deter-minations by the uricase method. Clin. Chem., 25, 1492-1494 (1979).
21. Jeha, S., Kantarjian, H., Irwin, D., Shen, V., Shenoy, S., Blaney, S., Camitta, B., and Pui, C. H., Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multi-center compassionate use trial. Leukemia, 19, 34-38 (2005).
22. Johnson, W. J., Stavric, B., and Chartrand, A., Uricase inhi-bition in the rat by s-triazines: an animal model for hyper-uricemia and hyperuricosuria. Proc. Soc Exp. Biol. Med., 131, 8-12 (1969).
23. Kang, D. H. and Nakagawa, T., Uric acid and chronic renal disease: possible implication of hyperuricemia on progres-sion of renal disease. Semin. Nephrol., 25, 43-49 (2005).
24. Kelly, S. J., Delnomdedieu, M., Oliverio, M. I., Williams, L. D., Saifer, M. G. P., Sherman, M. R, Coffman, T. M., Johnson, G. A., and Hershdield, M. S., Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J. Am. Soc Nephrol., 12, 1001-1009 (2001).
25. Kizer, N., Martinez, E., and Powell, M., Report of two cases of rasburicase-induced methemoglobinemia. Leuk. Lymphoma, 47, 2648-2650 (2006).
26. Kynclova, E., Elsner, E., Kopf, A., Hawa, G., Schalkhammer, T., and Pittner, F., Novel method for coupling of poly (ethylene glycol) to carboxylic acid moieties of proteins. J. Mol. Recognit., 9, 644-651 (1996).
27. Liao, F., Liu, W. L., Zhou, Q. X., Zeng, Z. C, and Zuo, Y. P., Assay of serum arylesterase activity by fitting to the reaction curve with an integrated rate equation. Clin. Chim. Acta, 314, 67-76 (2001).
28. Liao, F., Zhu, X. Y., Wang, Y. M., and Zuo, Y. P., The compar-ison on the estimation of kinetic parameters by fitting enzyme reaction curve to the integrated rate equation of different predictor variables. J. Biochem. Biophys. Methods, 62, 13-24 (2005).
29. Liao, F., Zhao, Y. S., Zhao, L. N., Tao, J., Zhu, X. Y, and Liu, L., Evaluation of a kinetic uricase method for serum uric acid assay by predicting background absorbance of uricase reaction solution with an integrated method. J. Zhejiang Univ. Sci. B, 7, 497-502 (2006).
30. Liao, F., Yang, D. Y., Tang, J. Q., Yang, X. L., Liu, B. Z., Zhao, Y. S., Zhao, L. N., Liao, H., and Yu, M. A, The mea-surement of serum cholinesterase activities by an integra-tion strategy with expanded linear ranges and negligible substrate-activation. Clin. Biochem., 42, 926-928 (2009).
31. Liu, B. Z, Zhao, Y. S, Zhao, L. N., Xie, Y. L, Zhu, S, Li, Z. R, Liu, Y, Lu, W, Yang, X. L, Xie, G. M, Zhong, H. S., Yu, M. A., Liao, H., and Liao, F., An integration strategy to estimate the initial rates of enzyme reactions with much expanded linear ranges using uricases as models. Anal. Chim. Acta, 631, 22-28 (2009a).
32. Liu, Z., Lu, D., Li, J., Chen, W., and Liu, Z., Strengthening intersubunit hydrogen bonds for enhanced stability of re-combinant urate oxidase from Aspergillus flavus: mole-cular simulations and experimental validation. Phys. Chem. Chem. Phys., 11, 333-340 (2009b).
33. Mene, P. and Punzo, G., Uric acid: bystander or culprit in hypertension and progressive renal disease? J. Hypertens., 26, 2085-2092 (2008).
34. Nguyen, M. T., Awale, S., Tezuka, Y, Shi, L., Zaidi, S. F., Ueda, J. Y, Tran, Q. L., Murakami, Y., Matsumoto, K., and Kadota, S., Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats. Biol. Pharm. Bull., 28, 2231-2234 (2005).
35. Ramazzina, I., Folli, C, Secchi, A., Berni, R., and Percudani, R., Completing the uric acid degradation pathway through phylogenetic comparison of whole genomes. Nat. Chem. Biol., 2, 144-148 (2006).
36. Sedor, F. A. and Sander, E. G., Inhibition of uricase by substituted pyrimidines. Biochem. Biophys. Res. Commun., 75, 406-413 (1977).
37. Sherman, M. R., Saifer, M. G. P., and Perez-Ruiz, F., PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev., 60, 59-68 (2008).
38. Stavric, B. and Nera, E. A., Use of the uricase-inhibited rat as an animal model in toxicology. Clin. Toxicol., 13, 47-74 (1978).
39. Sundy, J. S. and Hershfield, M. S., Uricase and other novel agents for the management of patients with treatment-failure gout. Curr. Rheumatol. Rep., 9, 258-264 (2007).
40. Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., and Hershfield, M. S., Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombi-nant mammalian urate oxidase in patients with refrac-tory gout. Arthritis Rheum., 56, 1021-1028 (2007).
41. Tan, Q. Y, Wang, N, Yang, H, Zhang, L. K., Liu, S, Chen, L., Liu, J., Zhang, L., Hu, N. N., Zhao, C. J., and Zhang, J. Q., Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int. J. Pharm., 384, 165-172 (2010).
42. Wu, X., Wakamiya, M., Vaishnav, S., Geske, R., Montgomery, C. M., Jones, P., Bradley, A., and Caskey, C. T., Hyperuri-cemia and urate nephropathy in urate oxidase-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 91, 742-746 (1994).
43. Yue, C. S., Huang, W, Alton, M., Maroli, A. N., Waltrip, R. W., Wright, D., and Marco, M. D., Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. J. Clin. Pharmacol., 48, 708-718 (2008).
44. Zhang, C, Yang, X. L, Feng, J, Yuan, Y. H, Li, X, Bu Y. Q-Xie, Y. L., Yuan, H. D., and Liao, F., Effects of modifica tion of amino groups with poly(Ethylene Glycol) on a recombinant uricase from Bacillus fastidiosus. Biosci. Biotechnol. Biochem., 74, 1298-1301 (2010).
45. Zhao, Y. S., Zhao, L. N., Yang, G. Q., Tao, J., Bu, Y. Q., and Liao, F., Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method. Biotechnol. Appl. Biochem., 45, 75-80 (2006).
46. Zhao, Y S, Yang, X. L, Li, X. Y, Bu, Y. Q., Deng, P, Zhang, C, Feng, J, Xie, Y. L, Zhu, S., Yuan, H. D, Yu, M. A., and Liao, F., Reversible inactivation of an intracellular uri-case from Bacillus fastidiosus via dissociation of homo-tetramer into homodimers in solutions of low ionic strength. Biosci. Biotechnol. Biochem., 73, 2141-2144 (2009a).
47. Zhao, Y. S, Yang, X. Y, Lu, W, Liao, H, and Liao, F, Uri-case based method for determination of uric acid in serum. Michrochim. Acta, 164, 1-6 (2009b).